Clinical Trial Update: Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants

View source ↗

Summary

An observational study evaluating natalizumab (Tysabri) in early relapsing-remitting multiple sclerosis patients who are anti-JC virus antibody negative has com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Tysabri (Natalizumab)

Snippet

Sponsor: Biogen | Conditions: Relapsing-Remitting Multiple Sclerosis | Status: COMPLETED